Skip to main content

Summary

at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

This study will follow subjects who completed the TED-C14-006 study. The purpose of this study is to evaluate the long-term safety and efficacy of teduglutide in pediatric subjects with Short Bowel Syndrome (SBS). This study will also offer teduglutide treatment to eligible subjects, regardless of treatment received in TED-C14-006.

Official Title

A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients With Short Bowel Syndrome Who Completed TED-C14-006

Keywords

Short Bowel Syndrome

Eligibility

You can join if…

  1. Subject provides written informed consent (subject, parent or legal guardian and, as appropriate, informed assent) to participate in the study before completing any study-related procedures.
  2. Subject completed the TED-C14-006 study (including subjects in the standard of care treatment arm).
  3. Subject understands and is willing and able to fully adhere to study requirements as defined in this protocol.

You CAN'T join if...

  1. There are no exclusion criteria for this study.

Locations

  • Childrens Hospital Los Angeles - RHU accepting new patients
    Los Angeles, California, 90027-6062, United States
  • Mattel Children's Hospital UCLA accepting new patients
    Los Angeles, California, 90095, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Shire
ID
NCT02954458
Phase
Phase 3
Lead Scientist
Sue Rhee
Study Type
Interventional
Last Updated
August 1, 2017
I’m interested in this study!